Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...
NYSE: NVS
Novartis’ Revolade Approved for Severe Aplastic Anemia in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving another indication approval from the National...
Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss...
Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released its financial results for Q4 and the...
Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE
China-based Qilu Pharmaceutical has announced that its market approval filing for a biosimilar version of...
Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...
Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA
China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...
Novartis China Establishes Health Development Fund in Boao Lecheng
Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China
Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...
Novartis Considers Sale of Non-Core Units to Fund Innovation
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...
Novartis Partners with Alibaba Health to Enhance Patient Medication Accessibility
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss...
Novartis’ Cosentyx Gains Approval for New Doses in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications...
Novartis Expands Strategic Collaboration with Bo’Ao Lecheng Pilot Zone
Novartis (NYSE: NVS) announced a further strategic collaboration with the Bo’Ao Lecheng Medical Tourism Pilot...
Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
Novartis Partners with Beijing’s Changping District to Expand Drug Development
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...
Novartis Aims for China to Be Second – Largest Market by 2024
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...